Navigating the regulatory landscape of the Bacterial Endotoxin Test (BET) involves a thorough review of guidelines from regulatory agencies such as the FDA, USP, and...

Key Findings• Every month a programme can accelerate to market adds an estimated $5–6M of net present value per billion dollars of peak year sales• We have identifie...

The bone marrow niche provides a tightly controlled setting where cellular interactions, biochemical signalling, and mechanical stimuli collectively shape the fate o...

Antibodies represent a rapidly growing therapeutic modality, demonstrating clinical success over a wide variety of diseases, including cancer, autoimmune disorders, ...

What is Biopharma 4.0? Biopharma 4.0 refers to the next-generation modernisation approach to biopharmaceutical development, manufacturing, and quality. It integrates...

Targeted Protein Degraders (TPDs) are transforming the landscape of modern drug discovery and development, introducing a ground-breaking method for tackling diseases...